Ozempic personality changes are reported online, but trials have not found that semaglutide changes personality or worsens mood. What people most often notice is quieter “food noise”, fewer cravings and a different relationship with eating. In January 2026, FDA reviewed 91 trials and more than 2 million patient records, found no increased risk of suicidal thoughts, depression or anxiety, and asked drugmakers to remove the suicide warning from weight-loss GLP-1 labels.[1]
For more on the drug itself, see our semaglutide profile.
What people mean by “personality changes”
Reports on social media and in clinics tend to fall into a few groups:
- Less interest in food: fewer cravings, less snacking, eating smaller portions.
- Quieter food noise: less time spent thinking about the next meal.
- Mood changes: some people report feeling better as they lose weight; others report irritability, low mood or feeling flat.
- Changes in other habits: some describe less interest in alcohol or other rewards.
Some of these effects are expected from how the drug works. Semaglutide acts on GLP-1 receptors in the brain areas that control appetite. The harder question is whether it affects mood directly, and that is where the trial data matter.
Food noise: what the research says
“Food noise” is not a medical diagnosis. It is a popular term for constant, intrusive thoughts about food.
A 2026 nationally representative survey of 1,000 US adults found:[6]
- 50.9% reported food noise at least occasionally, and 18.0% frequently.
- Frequent food noise was more common in women (22.7% vs 12.7% in men) and younger adults.
- Current and former GLP-1 users reported frequent food noise more often (25.8% and 26.8%) than non-users (16.3%).
That last finding does not mean GLP-1 drugs cause food noise. People who struggle most with intrusive food thoughts may be more likely to seek treatment. No controlled trial has yet measured whether semaglutide reduces food noise, so the many personal reports remain anecdotal.
Does Ozempic cause depression?
The best evidence comes from the STEP weight-loss trials, which screened participants for depression and suicidal thoughts throughout treatment.
A 2024 analysis of 3,377 participants in STEP 1, 2 and 3 found:[4]
- Depression scores (PHQ-9, a standard questionnaire) were low and similar at 68 weeks: 2.0 on semaglutide 2.4 mg vs 2.4 on placebo.
- People on semaglutide were less likely to move into a more severe depression category (odds ratio 0.63).
- Suicidal ideation or behavior was reported by 1% or fewer, with no difference between groups.
- Psychiatric adverse events were generally balanced between groups, and STEP 5 showed similar results.
These trials excluded people with recent major depression or other serious psychiatric conditions, so they say less about people with an existing mental illness.[4]
FDA’s 2026 meta-analysis of 91 placebo-controlled GLP-1 trials found no increased risk of depression, anxiety, irritability or psychosis.[1]
Suicidal thoughts: how the evidence developed
| Date | Agency or study | Finding |
|---|---|---|
| Jan 2024 | Nature Medicine cohort study | Semaglutide linked to lower risk of new suicidal ideation than other weight-loss medicines (hazard ratio 0.27)[5] |
| Jan 2024 | FDA preliminary evaluation | No evidence of a link found, but too few cases in trials to rule out a small risk[2][1] |
| Apr 2024 | European Medicines Agency (PRAC) | Available evidence does not support a causal link for semaglutide or other GLP-1 drugs[3] |
| Jan 2026 | FDA full review | No increased risk in 91 trials (107,910 patients) or in a cohort of 2,243,138 users; warning removal requested[1] |
| Feb 2026 | Wegovy label | Suicidal behavior and ideation warning removed[7] |
The European committee reviewed dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide, drawing on a large health-record study and its own cohort study in type 2 diabetes.[3]
The earlier warning only ever appeared on the weight-loss brands (Wegovy, Zepbound and Saxenda). Diabetes brands such as Ozempic never carried it.[1]
Anhedonia: feeling flat
Anhedonia means a reduced ability to feel pleasure. Because semaglutide acts on brain reward pathways that also respond to food, some researchers and patients have asked whether it could blunt enjoyment more broadly.
So far this rests on individual reports. The STEP trials did not find more psychiatric adverse events with semaglutide, and FDA’s review found no increase in depression.[4][1] But those studies did not measure anhedonia specifically, so a small effect in some people cannot be excluded. If you feel persistently flat, tell your prescriber.
Other reasons mood can change
Mood shifts during treatment do not always come from the drug’s direct effect on the brain:
- Side effects: ongoing nausea, poor sleep or fatigue can affect mood. See our guide to GLP-1 fatigue.
- Eating less: food is a source of comfort and social connection, and losing that can feel like a loss.
- Weight changes: weight loss can improve self-esteem for some and bring unexpected feelings for others.
- Alcohol: some people drink less on GLP-1 drugs. See GLP-1 drugs and alcohol.
Who may need closer monitoring
The trial evidence is reassuring, but it has limits. The STEP trials excluded people with known major psychiatric conditions, so the data are thinnest for the people who may be most vulnerable.[4] If you have a history of depression, anxiety, an eating disorder or self-harm, it is reasonable to:
- Tell your prescriber about your history before starting.
- Keep any existing mental health care in place.
- Ask a family member or friend to tell you if they notice changes in your mood or behavior.
- Plan a check-in after each dose increase, when side effects are most common.
FDA advises clinicians to refer patients who disclose suicidal thoughts or behavior to mental health professionals.[1]
What to do if you notice changes
- Track it: note when changes started, especially relative to a dose increase.
- Talk to your prescriber: do not stop on your own. FDA advises patients to keep taking the medicine as prescribed and to discuss concerns.[1]
- Get help for serious symptoms: thoughts of self-harm need urgent care; call or text 988 in the US.[1]
For what to expect from treatment overall, see semaglutide weight loss results and, if you are weighing a switch, semaglutide vs tirzepatide.
